Under the agreement, Smith & Nephew plc will buy Israel-based Cartiheal for an initial $180m in cash and up to $150m more contingent on financial performance, the companies announced on 22 November.
“The acquisition of this disruptive technology supports our strategy to invest behind our success sports medicine business,” said Deepak Nath, CEO of Smith & Nephew
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?